CEL-SCI Announces That The NYSE MKT Approves Plan Post author:Sam Post published:February 26, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like This Pharma Giant Doesn't Want Its Drug Used in Death Penalty Executions August 22, 2017 Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 Neothetics to Slash an Unknown Number of Jobs, Review Strategic Alternatives July 10, 2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017